started · updated
Health plans face challenges with high-cost rare disease therapies
At the AMCP Nexus 2026 meeting, Susan M. Wescott discussed the complexities health plans face when evaluating rare disease therapies. While new treatments offer hope to patients with previously untreatable conditions, the high costs and limited data present significant hurdles for payers.
Wescott noted that because many rare diseases affect small populations, plans must rely heavily on education, data gathering, and expert opinions to understand how specific therapies function. The financial implications are substantial; the U.S. healthcare system is approaching a turning point where some plans may struggle to afford these products, and self-insured plans could face bankruptcy following high-cost claims.
To manage these pressures, payment models are evolving, with plans increasingly joining larger groups to underwrite across broader populations. Despite financial constraints, coverage decisions remain centered on whether a drug significantly improves patient lives, often incorporating the patient voice and provider input into the assessment process.